GSK and Google parent forge $715 million bioelectronic medicines firm

A GlaxoSmithKline logo is seen outside one of its buildings in west London, February 6, 2008. REUTERS/Toby Melville/File Photo
A GlaxoSmithKline logo is seen outside one of its buildings in west London, February 6, 2008.

Reuters/Toby Melville/File Photo


GlaxoSmithKline and Google parent Alphabet’s life sciences unit are creating a new company focused on fighting diseases by targeting electrical signals in the body, jump-starting a novel field of medicine called bioelectronics.

Verily Life Sciences – known as Google’s life sciences unit until last year – and Britain’s biggest drugmaker will together contribute 540 million pounds ($715 million) over seven years to Galvani Bioelectronics, they said on Monday.

Pfizer acquires Bamboo Therapeutics to beef up gene therapy arsenal

A man walks past Pfizer's world headquarters in New York April 28, 2014.  REUTERS/Andrew Kelly/File Photo
A man walks past Pfizer’s world headquarters in New York April 28, 2014.

Reuters/Andrew Kelly/File Photo


Pfizer Inc said it had acquired privately held gene therapy developer Bamboo Therapeutics Inc in a deal worth up to $645 million to boost its presence in the treatment of rare diseases.

Research into gene therapy, which aims to insert corrective genes into malfunctioning cells, goes back a quarter of a century but the field has experienced multiple setbacks and been plagued by safety concerns.

Pfizer acquires Bamboo Therapeutics to beef up gene therapy arsenal

A man walks past Pfizer's world headquarters in New York April 28, 2014.  REUTERS/Andrew Kelly/File Photo
A man walks past Pfizer’s world headquarters in New York April 28, 2014.

Reuters/Andrew Kelly/File Photo


Pfizer Inc said it had acquired privately held gene therapy developer Bamboo Therapeutics Inc in a deal worth up to $645 million to boost its presence in the treatment of rare diseases.

Research into gene therapy, which aims to insert corrective genes into malfunctioning cells, goes back a quarter of a century but the field has experienced multiple setbacks and been plagued by safety concerns.

No Dementia Prevention With Vascular Care

Action Points

  • Note that this randomized trial in The Netherlands demonstrated no protective effect of a multi-modality cardiovascular intervention to reduce the incidence of dementia.
  • Be aware that the “standard of care” arm received very good care, given the nature of the Dutch healthcare system.

TORONTO — Intense vascular risk management failed to prevent dementia in a large pragmatic trial in The Netherlands, researchers reported here.

No Dementia Prevention With Vascular Care

Action Points

  • Note that this randomized trial in The Netherlands demonstrated no protective effect of a multi-modality cardiovascular intervention to reduce the incidence of dementia.
  • Be aware that the “standard of care” arm received very good care, given the nature of the Dutch healthcare system.

TORONTO — Intense vascular risk management failed to prevent dementia in a large pragmatic trial in The Netherlands, researchers reported here.

Take the easy step to protect yourself from pneumonia

Did you know that 1,000,000 Americans go to the hospital with pneumonia every year? Pneumonia is a lung infection caused by pneumococcal disease, which can also cause blood infections and meningitis. The bacteria that causes pneumococcal disease is spread by direct person-to-person contact. There’s a vaccine to help prevent pneumonia, but only 61% of adults 65 and over have ever gotten it.

Medicare can help protect you from pneumococcal infections. The pneumococcal shot is the best way to help prevent these infections. Medicare Part B covers the shot and a second shot one year after you got the first shot.

Take the easy step to protect yourself from pneumonia

Did you know that 1,000,000 Americans go to the hospital with pneumonia every year? Pneumonia is a lung infection caused by pneumococcal disease, which can also cause blood infections and meningitis. The bacteria that causes pneumococcal disease is spread by direct person-to-person contact. There’s a vaccine to help prevent pneumonia, but only 61% of adults 65 and over have ever gotten it.

Medicare can help protect you from pneumococcal infections. The pneumococcal shot is the best way to help prevent these infections. Medicare Part B covers the shot and a second shot one year after you got the first shot.